Read by QxMD icon Read

Pathological response in breast cancer

Qian Wang, Chunmei Li, Peipei Tang, Runyuan Ji, Song Chen, Jian Wen
BACKGROUND/AIMS: Triple-negative breast cancer (TNBC) is a highly aggressive malignancy that responds in a diverse manner to neoadjuvant chemotherapy (NAC). This study was aimed to uncover an RNA signature in TNBC patients which predicts pathological complete responses (pCR) to NAC by analyzing long noncoding RNA (lncRNA) and coding gene expression. METHODS: Microarray datasets from 26 TNBC patients receiving NAC including ten patients showing pCR were obtained from the Gene Expression Omnibus database...
August 17, 2018: Cellular Physiology and Biochemistry
Nilgun Yildirim, Aykut Bahceci
Trastuzumab and pertuzumab are monoclonal antibodies used for the treatment of breast cancer. Until now, there have been no reports on the use of pertuzumab during pregnancy and on its potential effects on the fetus. Herein, we present a breast cancer patient who received trastuzumab and pertuzumab treatment during the first 20 weeks of pregnancy. This 22-year-old patient initially diagnosed with invasive ductal carcinoma of the breast was found to be negative for estrogen receptor and progesterone receptor and positive for human epidermal growth factor receptor in the immunohistochemical examination...
September 2018: Anti-cancer Drugs
Bo Wang, Dongping Li, Rocio Rodriguez-Juarez, Allison Farfus, Quinn Storozynsky, Megan Malach, Emily Carpenter, Jody Filkowski, Anne E Lykkesfeldt, Olga Kovalchuk
BACKGROUND: Breast cancer is the most common malignancy in women worldwide. Although the endocrine therapy that targets estrogen receptor α (ERα) signaling has been well established as an effective adjuvant treatment for patients with ERα-positive breast cancers, long-term exposure may eventually lead to the development of acquired resistance to the anti-estrogen drugs, such as fulvestrant and tamoxifen. A better understanding of the mechanisms underlying antiestrogen resistance and identification of the key molecules involved may help in overcoming antiestrogen resistance in breast cancer...
August 13, 2018: BMC Cancer
Loïc Lelièvre, Philippe Clézardin, Laurent Magaud, Laurent Roche, Nicole Tubiana-Mathieu, Jean-Dominique Tigaud, Delphine Topart, Nadia Raban, Marie-Ange Mouret-Reynier, Patrice Mathevet
INTRODUCTION: Neoadjuvant chemotherapy has become the treatment of choice for locally advanced breast cancer. Zoledronic acid (ZA) is a bisphosphonate initially used in the treatment of bone metastases because of its antibone resorption effect. Antitumor effects of ZA, including the inhibition of cell adhesion to mineralized bone or the antiangiogenic effect, have been demonstrated. However, the clinical significance of these effects remains to be determined. MATERIALS AND METHODS: We undertook a multicenter open-label randomized trial to analyze the value of adding ZA to neoadjuvant chemotherapy for TNM clinical stage T2/T3 breast cancer...
July 10, 2018: Clinical Breast Cancer
John Brodersen, Volkert Siersma, Hanne Thorsen
BACKGROUND: Cervical cancer screening will inevitably lead to unintentional harmful effects e.g. detection of indolent pathological conditions defined as overdetection or overdiagnosis. Overdiagnosis often leads to overutilisation, overtreatment, labelling and thereby negative psychosocial consequences. There is a lack of adequate psychosocial measures when it comes to measurement of the harms of medical screening. However, the Consequences of Screening questionnaire (COS) has been found relevant and comprehensive with adequate psychometric properties in breast and lung cancer screening...
August 10, 2018: BMC Psychology
Yoshitaka Fujiki, Yutaka Yamamoto, Aiko Sueta, Mutsuko Yamamoto-Ibusuki, Lisa Goto-Yamaguchi, Mai Tomiguchi, Takashi Takeshita, Hirotaka Iwase
Background: Apolipoprotein B mRNA editing enzyme catalytic polypeptide-like 3B (APOBEC3B) is a gene editing enzyme with cytidine deaminase activity and high expression of its mRNA in breast tumors have been shown to be associated with progressive cases and poor prognosis. In this study, we aimed to examine the relationship between the expression of APOBEC3B and the effect of neoadjuvant chemotherapy (NAC) using pretreatment biopsy tissue, and examined whether the expression of APOBEC3B influenced chemotherapy efficacy...
July 17, 2018: Oncotarget
Yanal Alnimer, Zakaria Hindi, Khalil Katato
Introduction: Multiple trials demonstrated that adding Bevacizumab to the standard neoadjuvant chemotherapy in HER-2 negative breast cancer increases pathological complete response. We conducted this meta-analysis to evaluate that effect on survival. Methods: We performed a systematic search for randomized trials measuring the effect of adding either neoadjuvant or adjuvant Bevacizumab to the standard chemotherapy on disease-free and overall survival in breast cancer surgical candidates...
2018: Breast Cancer: Basic and Clinical Research
Bo Chen, Weidong Wei, Xiaojia Huang, Xinhua Xie, Yanan Kong, Danian Dai, Lu Yang, Jin Wang, Hailin Tang, Xiaoming Xie
Circular RNAs (circRNAs) represent a class of non-coding RNAs that play a vital role in modulating gene expression and several pathological responses. However, the expression profile and function of circRNAs in triple-negative breast cancer (TNBC) remain unknown. In the current study, we investigated the expression profile of human circRNAs in TNBC tissues and identified circEPSTI1 (hsa_ circRNA_000479) as a significantly upregulated circRNA. Methods: We performed circular RNA microarray assays to screen circular RNA expression profiles of TNBC and further investigated circEPSTI1...
2018: Theranostics
Shaimaa Elzamly, Nabeel Badri, Osvaldo Padilla, Alok Kumar Dwivedi, Luis A Alvarado, Matthew Hamilton, Nabih Diab, Crosby Rock, Ahmed Elfar, Marwa Teleb, Luis Sanchez, Zeina Nahleh
The association between pathologic complete response (pCR) following to neoadjuvant chemotherapy (NAC) and the improved survival in breast cancer has been previously reported. The aim of this study was is to explore the expression of several biomarkers described during epithelial-mesenchymal transition (EMT) and the achievement of pCR in different molecular subtypes of breast cancer. We identified archived pathology tissue from patients with breast cancer who received NAC during the year 2014. We performed immunohistochemical analysis of vimentin, nuclear factor κB (NF-κB), epidermal growth factor receptor (EGFR), E-cadherin, estrogen receptor (ER), progesterone receptor, and Her2neu and studied the association between the expression of these markers and pCR...
2018: Breast Cancer: Basic and Clinical Research
Rajinder Parshad, Mufaddal Kazi, V Seenu, Sandeep Mathur, Siddharth Dattagupta, K P Haresh
BACKGROUND: Triple-negative breast cancers (TNBCs) are known for early age at presentation, large tumor sizes, and overall poor prognosis. However, Indian studies are scarce with limited follow-up data. Hence, the present study is aimed at characterizing nonmetastatic TNBC patients in our population and comparing their outcome with non-TNBC subset. METHODOLOGY: This is a retrospective observational study of nonmetastatic breast cancer patients accrued over 14 years...
October 2017: Indian Journal of Cancer
Shanmugam Subbiah, Govindasamy Gopu, P Senthilkumar, P Muniasamy
PURPOSE: The objective of this study was to assess response to neoadjuvant chemotherapy in molecular subtypes of breast cancer. METHODS: This study included 60 patients with locally advanced and metastatic breast cancer. The authors excluded patients who already underwent mastectomy or were given any chemotherapy/radiotherapy. They analyzed the clinical and immunohistochemical characteristics using core biopsy specimens to determine their correlations with response to chemotherapy...
October 2017: Indian Journal of Cancer
Rashmi K Murthy, Akshara S Raghavendra, Kenneth R Hess, Takeo Fujii, Bora Lim, Carlos H Barcenas, Hong Zhang, Mariana Chavez-Mac-Gregor, Elizabeth A Mittendorf, Jennifer K Litton, Sharon H Giordano, Alastair M Thompson, Vicente Valero, Stacy L Moulder, Debu Tripathy, Naoto T Ueno
INTRODUCTION: Several human epidermal growth factor 2 (HER2)-targeted regimens are used to treat HER2-positive (HER2+ ) breast cancer (BC). The goal of this study was to retrospectively determine the pathologic complete response (pCR) rate for trastuzumab and pertuzumab (HP)-containing regimens compared with trastuzumab (H)-containing regimens for stage II to III HER2+ BC. PATIENTS AND METHODS: Patients (n = 977) with stage II to III HER2+ BC who received neoadjuvant HER2-targeted therapy from 2005 to 2016 and underwent definitive breast and axillary lymph node surgery were identified...
July 10, 2018: Clinical Breast Cancer
Mustafa Kahraman, Anne Röske, Thomas Laufer, Tobias Fehlmann, Christina Backes, Fabian Kern, Jochen Kohlhaas, Hannah Schrörs, Anna Saiz, Cassandra Zabler, Nicole Ludwig, Peter A Fasching, Reiner Strick, Matthias Rübner, Matthias W Beckmann, Eckart Meese, Andreas Keller, Michael G Schrauder
Breast cancer is a heterogeneous disease with distinct molecular subtypes including the aggressive subtype triple-negative breast cancer (TNBC). We compared blood-borne miRNA signatures of early-stage basal-like (cytokeratin-CK5-positive) TNBC patients to age-matched controls. The miRNAs of TNBC patients were assessed prior to and following platinum-based neoadjuvant chemotherapy (NCT). After an exploratory genome-wide study on 21 cases and 21 controls using microarrays, the identified signatures were verified independently in two laboratories on the same and a new cohort by RT-qPCR...
August 2, 2018: Scientific Reports
Takashi Kuwayama, Seigo Nakamura, Naoki Hayashi, Toshimi Takano, Koichiro Tsugawa, Takanobu Sato, Akira Kitani, Hiromi Okuyama, Hideko Yamauchi
BACKGROUND: Weekly nanoparticle albumin-bound paclitaxel (nab-paclitaxel) demonstrated greater efficacy with less toxicity than docetaxel in metastatic breast cancer. We conducted a randomized phase II to compare these regimens as neoadjuvant chemotherapy for HER2- early-stage breast cancer. PATIENTS AND METHODS: Stage I-III human epidermal growth factor receptor-negative (HER2- ) breast cancer patients were included in the present trial and received either docetaxel every 3 weeks or nab-paclitaxel on days 1, 8, and 15 every 28 days for 4 cycles, followed by FEC (5-fluorouracil, epirubicin, cyclophosphamide) every 3 weeks for 4 cycles...
June 27, 2018: Clinical Breast Cancer
Andrés López-Cortés, Paola E Leone, Byron Freire-Paspuel, Nathaly Arcos-Villacís, Patricia Guevara-Ramírez, Felipe Rosales, César Paz-Y-Miño
Breast cancer is the leading cause of cancer-related death among women worldwide. AKT1 encodes the kinase B alpha protein. The rs121434592, rs12881616, rs11555432, rs11555431, rs2494732, and rs3803304 single nucleotide polymorphisms have been identified in the AKT1 kinase gene. Activated AKT1 phosphorylates downstream substrates regulating cell growth, metabolism, apoptosis, angiogenesis, and drug responses. It is essential to know how breast cancer risk is associated with histopathological and immunohistochemical characteristics and genotype polymorphisms in a high altitude Ecuadorian mestizo population...
2018: BioMed Research International
Jessalyn M Ubellacker, Ninib Baryawno, Nicolas Severe, Molly J DeCristo, Jaclyn Sceneay, John N Hutchinson, Marie-Therese Haider, Catherine S Rhee, Yuanbo Qin, Walter M Gregory, Ana C Garrido-Castro, Ingunn Holen, Janet E Brown, Robert E Coleman, David T Scadden, Sandra S McAllister
The presence of disseminated tumor cells in breast cancer patient bone marrow aspirates predicts decreased recurrence-free survival. Although it is appreciated that physiological, pathological, and therapeutic conditions impact hematopoiesis, it remains unclear if targeting hematopoiesis presents opportunities for limiting bone metastasis. Using pre-clinical breast cancer models, we discovered that marrow from mice treated with the bisphosphonate zoledronic acid (ZA) are metastasis-suppressive. Specifically, ZA modulated hematopoietic myeloid/osteoclast progenitor cell (M/OCP) lineage potential to activate metastasis-suppressive activity...
July 31, 2018: Cancer Research
Priyanka Sharma, Sara López-Tarruella, Jose A Garcia-Saenz, Qamar J Khan, Henry Gomez, Aleix Prat, Fernando Moreno, Yolanda Jerez-Gilarranz, Agustí Barnadas, Antoni C Picornell, Maria Del Monte-Millán, Milagros Gonzalez-Rivera, Tatiana Massarrah, Beatriz Pelaez-Lorenzo, María Isabel Palomero, Ricardo González Del Val, Javier Cortes, Hugo Fuentes Rivera, Denisse Bretel Morales, Ivan Marquez-Rodas, Charles M Perou, Carolyn Lehn, Yen Y Wang, Jennifer R Klemp, Joshua M Mammen, Jamie Wagner, Amanda Amin, Anne P O'Dea, Jaimie Heldstab, Roy A Jensen, Bruce F Kimler, Andrew K Godwin, Miguel Martín
PURPOSE: Prognostic value of pCR and extent of pathological response attained with anthracycline-free platinum plus taxane neoadjuvant chemotherapy (NAC) in TNBC is unknown. We report recurrence-free survival (RFS) and overall survival (OS) according to degree of pathological response in patients treated with carboplatin (Cb) plus docetaxel (D) NAC. EXPERIMENTAL DESIGN: 190 patients with stage I-III TNBC were treated with neoadjuvant Cb(AUC6) plus D(75mg/m2 ) every 21 days x 6 cycles...
July 30, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Marie Viala, Akiko Chiba, Simon Thezenas, Laure Delmond, Pierre-Jean Lamy, Sarah L Mott, Mary C Schroeder, Alexandra Thomas, William Jacot
BACKGROUND: There has been interest in the potential benefit of vitamin D (VD) to improve breast cancer outcomes. Pre-clinical studies suggest VD enhances chemotherapy-induced cell death. Vitamin D deficiency was associated with not attaining a pathologic complete response (pCR) following neoadjuvant chemotherapy (NAC) for operable breast cancer. We report the impact of VD on pCR and survival in an expanded cohort. METHODS: Patients from Iowa and Montpellier registries who had serum VD level measured before or during NAC were included...
July 30, 2018: BMC Cancer
Paul Gass, Michael Untch, Volkmar Müller, Volker Möbus, Christoph Thomssen, Lothar Häberle, Ramona Erber, Alexander Hein, Sebastian Michael Jud, Michael P Lux, Carolin C Hack, Arndt Hartmann, Hans-Christian Kolberg, Johannes Ettl, Diana Lüftner, Christian Jackisch, Matthias W Beckmann, Wolfgang Janni, Andreas Schneeweiss, Peter A Fasching, Naiba Nabieva
Background: In women with early breast cancer, a pathological complete response (pCR) after neoadjuvant chemotherapy is reported to be associated with an improvement of the survival. The aim of this survey among physicians was to investigate whether the probability of achieving pCR in patients with a hormone receptor-positive, HER2-negative disease encourages physicians to recommend neoadjuvant chemotherapy. Methods: The study was conducted via an online survey that was sent to 493 physicians, who were either known as members of national guideline committees, heads of breast cancer centers, being high recruiters in clinical trials or leading a private practice...
July 2018: Geburtshilfe und Frauenheilkunde
I T Rubio, L Wyld, F Cardoso, G Curigliano, T Kovacs, P Poortmans, J Cortes
Preoperative systemic therapy (PST) has become an accepted treatment not only for locally advanced but also for early stage breast cancer patients. Clinical trials have demonstrated that the use of PST is equally to adjuvant treatments in terms of overall survival, and has the advantage of increasing rates of breast conservative surgery and rates of pathologic complete response, a surrogate endpoint for the effectiveness of systemic therapy. Initial studies have suggested higher rates of locoregional recurrence with this approach...
July 23, 2018: Breast: Official Journal of the European Society of Mastology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"